TABLE 1.
Small-molecular TFEB activators and their pharmacological targets.
| Pharmacological targets | Name of compounds | References |
|---|---|---|
| TFEB expression | PPARα agonists (e.g., GW7647, cinnamic acid) | Kim et al. (2017), Chandra et al. (2019) |
| Other compounds (genistein, ATRA, GDC-0941, luteolin) | Moskot et al. (2014), Orfali et al. (2020), Enzenmuller et al. (2013), Xu et al. (2020a) | |
| TFEB synthesis | Polyamines (e.g., spermidine) | Zhang et al. (2019), Puleston et al. (2019) |
| TFEB binding | Curcumin and analogues (e.g., curcumin-c1) | Zhang et al. (2016), Song et al. (2016) |
| mTOR inhibition | Tool mTOR inhibitors (e.g. torin-1, rapamycin) | Xu et al. (2020b), Chen et al. (2021) |
| Flavonoids (e.g., quercetin) | Huang et al. (2018) | |
| Polyphenols (e.g., 3,4-dimethoxychalcone, chlorogenic acid) | Chen et al. (2019b), Gao et al. (2020) | |
| Ca2+/calcineurin modulation | Na+/K+-ATPase inhibitors (e.g., digoxin, Ouabain) | Wang et al. (2017), Song et al. (2019b) |
| Other compounds (bedaquiline, liraglutide, carbon monoxide | Kim et al. (2018), Giraud-Gatineau et al. (2020), Fang et al. (2020b) | |
| AMPK/SIRT1 activation | Resveratrol, licochalcone A | Huang et al. (2019), Lv et al. (2019) |
| Akt activation | Trehalose | Sharma et al. (2021) |
| ROS generation | Docetaxel, sulforaphane | Zhang et al. (2018), Li et al. (2021b) |
| TFEB dephosphorylation | Acacetin | Ammanathan et al. (2020) |
| TFEB nuclear translocation | Naringenin, Apigenin | Jin et al. (2017), Li et al. (2017) |